XCUR FXN
Alternative Names: XCUR-FXNLatest Information Update: 28 Dec 2021
At a glance
- Originator Exicure
- Class Neuroprotectants; Oligonucleotides
- Mechanism of Action Frataxin expression stimulants; Protein biosynthesis modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Friedreich's ataxia
Most Recent Events
- 28 Dec 2021 Suspended - Preclinical for Friedreich's ataxia in USA (Intrathecal)
- 20 Aug 2021 Adverse events and pharmacodynamics data from a preclinical study in Friedreich's ataxia presented at released by Exicure R and D day (July 15,
- 29 Jun 2021 Preclinical trials in Friedreich's ataxia in USA (Intrathecal) before June 2021